As for site-specific cancers, liver cancer (11.9 per 10,000 patients per year) showed the highest incidence rate in the insulin use cohort, while lung cancer (12.0 per 10,000 patients per year) exhibited the highest incidence rate in the non-insulin use cohort. Here, INS is linked to lung carcinoma.